Evidence map›Paper›PMID 37546045›Full record

ArticleCureus2023

A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment.

Shaunak Mangeshkar, Natalia Nazarenko, Dimitrios Varrias, Michail Spanos, Pawel Borkowski, Majd Al Deen Alhuarrat, Weijia Li, Preeti Kishore, Robert T Faillace

Abstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shaunak MangeshkarInternal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, USA.
Natalia NazarenkoInternal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, USA.
Dimitrios VarriasInternal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, USA.
Michail SpanosCardiovascular Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Pawel BorkowskiInternal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, USA.
Majd Al Deen AlhuarratInternal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, USA.
Weijia LiCardiology, AdventHealth Orlando, Orlando, USA.
Preeti KishoreMedicine, Jacobi Medical Center, New York, USA.
Robert T FaillaceInternal Medicine, Albert Einstein College of Medicine, Jacobi Medical Center, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type V hyperlipoproteinemia or multifactorial chylomicronemia syndrome is a rare lipid disorder triggered mainly by uncontrolled diabetes, obesity, poor diet, or particular medications. It is associated with an increased risk of acute pancreatitis and accelerated coronary artery disease which may manifest in younger age groups. We present a case of a 42-year-old male who presented to the emergency department (ED) complaining of a non-healing hand injury. Upon laboratory workup, the patient was found to have an elevated total cholesterol (TC) of 1129 mg/dL, very low levels of high-density lipoprotein (HDL) and triglycerides (TG) > 4000 mg/dL with an inability to calculate low-density lipoprotein (LDL). Lipoprotein electrophoresis revealed an actual TG level of > 7000 mg/dL, increased chylomicrons, normal B and pre-B-lipoproteins, and increased L-lipoproteins with an elevated Apolipoprotein B. Despite these derangements, the patient did not exhibit any abdominal complaints, demonstrating a normal lipase level. The physical exam was indicative of bilateral arcus senilis and obesity. Insulin drip was initiated along with intravenous (IV) hydration and it required 12 days to bring triglycerides down to less than 1000 mg/dL. The total cholesterol was also seen to be down trending to around 500 mg/dL and the HDL improved to 22 mg/dL. We present this case as a unique presentation of asymptomatic chylomicronemia resistant to insulin treatment with an elevated ApoB but with no evidence of pancreatitis or coronary artery disease.

Indexed as

cardiovascular diseasehypertriglyceridemia induced pancreatitisinsulin resistancemultifactorial chylomicronemia syndromesevere hypertriglyceridemia

Identifiers

PMID37546045
PMCPMC10403339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.